Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Soriot’s Vision For AZ: A Focused Innovation-Driven Biopharma

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.

You may also be interested in...



Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research

The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.

European Notebook: Pricing Reforms Debated In EU; Biosimilar Infliximab; AstraZeneca's HQ Build

European policymakers look at options such as greater information exchange between countries to strengthen price negotiation, joint procurement, and more collaborative HTA reviews to help hold down the high prices of certain medicines; Hospira expands its biosimilar infliximab into major markets.

AstraZeneca Makes Case For Independence With $23 Bil. Pipeline Potential

The U.K. drug maker went on the offense against Pfizer’s hostile takeover attempt May 6, laying out to investors its long-term revenue guidance forecasting $45 billion in revenues by 2023. Growth will be driven by a pipeline with $23 billion in peak sales potential.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel